Lucas A. Berenbrok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucas A. Berenbrok has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Kim Coccodrilli Coley
Professor of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA
7 shared publications - Inmaculada Hernandez
University of California San Diego
5 shared publications - Elaine Mormer
Vice Chair for Clinical Education and Professor, Department of Communication Science and Disorders, University of Pittsburgh, Pittsburgh, PA
4 shared publications - Melissa Somma McGivney
University of Pittsburgh School of Pharmacy, Pittsburgh, PA
4 shared publications - Erika N. Dreikorn
University of Pittsburgh, Clinical Translational Science Institute
3 shared publications - Jingchuan Guo
Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, USA
3 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 67 (1)
Descriptive analysis of pharmacy closures and openings in the United States from 2022 to 2024
- 17 October 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 67 (1)
Open AccessDescriptive analysis of pharmacy closures and openings in the United States from 2022 to 2024
- 30 September 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics
Commercial laboratories often have differing approaches to pharmacogenomic testing, which detects the presence of germline genetic variants associated with drug response. Setting standards for clinical laboratories and defining criteria for clinicians to consider when choosing a testing laboratory can help maximize the benefits of pharmacogenomics. Here, we propose specific laboratory practices that should be discontinued or established and followed as standard practice. We also propose ideal practices that would advance pharmacogenomics in clinical care.
- 30 September 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics
Commercial laboratories often have differing approaches to pharmacogenomic testing, which detects the presence of germline genetic variants associated with drug response. Setting standards for clinical laboratories and defining criteria for clinicians to consider when choosing a testing laboratory can help maximize the benefits of pharmacogenomics. Here, we propose specific laboratory practices that should be discontinued or established and followed as standard practice. We also propose ideal practices that would advance pharmacogenomics in clinical care.
- Open Access
- 22 September 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (10) , qxag256
Building on the 2025 National Academies Pharmacy Workshop: pharmacy deserts in the United States
Areas with no access or limited access to community pharmacies are routinely referred to as “pharmacy deserts,” which are of growing concern in the United States. In addition to medication dispensing, community pharmacies offer a variety of healthcare services that keep populations and individuals healthy. Our objective is to present an overview of pharmacy deserts in the United States, discuss the impact of reduced pharmacy access for Americans, and propose solutions discussed at the 2025 Innovations in Pharmacy Training and Sustainable Practice to Advance Patient Care: A Workshop at the National Academies in Washington, D.C. Policy and legislation that ensure the financial sustainability of community pharmacies as staples of healthcare delivery in local neighborhoods should consider these multimodal solutions to ensure pharmacy access for all populations in the United States.
- 22 September 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (10) , qxag256
Open AccessBuilding on the 2025 National Academies Pharmacy Workshop: pharmacy deserts in the United States
Areas with no access or limited access to community pharmacies are routinely referred to as “pharmacy deserts,” which are of growing concern in the United States. In addition to medication dispensing, community pharmacies offer a variety of healthcare services that keep populations and individuals healthy. Our objective is to present an overview of pharmacy deserts in the United States, discuss the impact of reduced pharmacy access for Americans, and propose solutions discussed at the 2025 Innovations in Pharmacy Training and Sustainable Practice to Advance Patient Care: A Workshop at the National Academies in Washington, D.C. Policy and legislation that ensure the financial sustainability of community pharmacies as staples of healthcare delivery in local neighborhoods should consider these multimodal solutions to ensure pharmacy access for all populations in the United States.
- 1 September 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (6)
Lessons for the remaining U.S. states seeking pharmacist authority to prescribe self-administered hormonal contraceptives
- 1 September 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (6)
Lessons for the remaining U.S. states seeking pharmacist authority to prescribe self-administered hormonal contraceptives
- 12 July 2026
- Published by Springer Nature
- p. 1-18
Pharmacogenomics Implementation in Family Medicine
- 20 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102934
Addressing pharmacy access in a landscape of pharmacy closures
- 20 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102934
Addressing pharmacy access in a landscape of pharmacy closures
- Open Access
- 8 November 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 543
Utilizing Pharmacogenetic Results to Optimize Medication Management in Hospice Care: A Pilot Study
Background: Pharmacogenetics (PGx), which examines how genetic variations influence drug metabolism and response, offers promise in hospice care where patients commonly experience polypharmacy, complex symptoms, and limited life expectancy. This study assessed the utility of PGx results in guiding medication adjustments to improve symptom management at the end of life. Methods: A retrospective chart review was conducted on ten patients enrolled in a Precision Hospice Program who had PGx results for six key metabolic genes. A PGx-trained pharmacist reviewed Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline-based recommendations, which were discussed during interdisciplinary hospice team meetings. Results: Patients had a mean age of 85.7 years and were prescribed an average of 17.9 medications. Among the 27 prescriptions reviewed, actionable gene–drug interactions were identified, primarily involving antidepressants and analgesics. Three patients underwent medication changes based on PGx guidance, including switching from citalopram to bupropion and adding morphine to tramadol therapy, which improved symptom control. Conclusion: While not yet routinely implemented in hospice settings, this pilot study suggests PGx-guided prescribing can support personalized medication decisions and enhance emotional and physical comfort in end-of-life care when test results are available.
- 8 November 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 543
Open AccessUtilizing Pharmacogenetic Results to Optimize Medication Management in Hospice Care: A Pilot Study
Background: Pharmacogenetics (PGx), which examines how genetic variations influence drug metabolism and response, offers promise in hospice care where patients commonly experience polypharmacy, complex symptoms, and limited life expectancy. This study assessed the utility of PGx results in guiding medication adjustments to improve symptom management at the end of life. Methods: A retrospective chart review was conducted on ten patients enrolled in a Precision Hospice Program who had PGx results for six key metabolic genes. A PGx-trained pharmacist reviewed Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline-based recommendations, which were discussed during interdisciplinary hospice team meetings. Results: Patients had a mean age of 85.7 years and were prescribed an average of 17.9 medications. Among the 27 prescriptions reviewed, actionable gene–drug interactions were identified, primarily involving antidepressants and analgesics. Three patients underwent medication changes based on PGx guidance, including switching from citalopram to bupropion and adding morphine to tramadol therapy, which improved symptom control. Conclusion: While not yet routinely implemented in hospice settings, this pilot study suggests PGx-guided prescribing can support personalized medication decisions and enhance emotional and physical comfort in end-of-life care when test results are available.
- Open Access
- 25 August 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (6) , 102912
Understanding clinician support preferences related to the use of pharmacogenomic results in electronic health records: A qualitative study in an academic health system
- 25 August 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (6) , 102912
Open AccessUnderstanding clinician support preferences related to the use of pharmacogenomic results in electronic health records: A qualitative study in an academic health system
- 18 July 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (6) , 102464
Encouraging OTC naloxone accessibility across the United States
- 18 July 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (6) , 102464
Encouraging OTC naloxone accessibility across the United States